Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 with concurrent radiotherapy vs radiotherapy alone in elderly esophageal squamous carcinoma
ChiCTR-IPR-17010668Phase 4Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tegafur in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: treatment toxicity and objective remission rate. Started Feb 2017; status: completed.
02
Drugs
tegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-IPR-17010668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010668.